TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34890827

Group type: EXPERIMENTAL
Intervention: Peanut Oral Immunotherapy (POIT) with a daily maintenance dose of 3,900 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Peanut Oral Immunotherapy (POIT) during maintenance
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Peanut Oral Immunotherapy (POIT) after 1-month treatment discontinuation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Biomarker analysis during POIT
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Biomarker analysis after 1-month discontinuation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DBPCFC reaction severity after 12 months
Number of subjects: 12
Study: 32358262

Group type: EXPERIMENTAL
Intervention: FineVision Pod FT toric IOL
Number of subjects: 60

Group type: COMPARATOR
Intervention: AcrySof IQ PanOptix toric IOL
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 34635511

Group type: EXPERIMENTAL
Intervention: FullFix intervention plus standard AOD care
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard AOD care alone
Number of subjects: 130
Study: 35773714

Group type: EXPERIMENTAL
Intervention: Social Competence Promotion Program among Young Adolescents (SCPP-YA)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard school preventive curricula
Number of subjects: 600
Study: 33542290

Group type: EXPERIMENTAL
Intervention: Airborne infrasound (IS; 6 Hz, 80-90 dB)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham devices
Number of subjects: 38
Study: 34437756

Group type: EXPERIMENTAL
Intervention: App-based treatment
Number of subjects: 262

Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 262

Group type: COMPARATOR
Intervention: Comparison of app vs care-as-usual
Number of subjects: 262
Study: 33420257

Group type: EXPERIMENTAL
Intervention: Improved duck health and nutrition interventions
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study: 36350379

Group type: EXPERIMENTAL
Intervention: e‐enabled lifestyle intervention (WWACP)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 351
Study: 34001519

Group type: EXPERIMENTAL
Intervention: VEA intervention (community-driven water, sanitation and hygiene intervention)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 332
Study: 35226532

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 33041017

Group type: EXPERIMENTAL
Intervention: Group A (discharge day 3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group B (discharge day 5)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 34967805

Group type: EXPERIMENTAL
Intervention: Preincision local anesthetic injection
Number of subjects: 24

Group type: COMPARATOR
Intervention: Postprocedure local anesthetic injection
Number of subjects: 24
Study: 32756520

Group type: EXPERIMENTAL
Intervention: Preoperative peripheral nerve block (PNB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (morphine as primary analgesic)
Number of subjects: 60
Study: 35954651

Group type: EXPERIMENTAL
Intervention: EG3s (eccentric contraction execution time = 3 s)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: EG6s (eccentric contraction execution time = 6 s)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: EG3s and EG6s
Number of subjects: 50
Study: 34274044

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 25 mg/day
Number of subjects: 52

Group type: COMPARATOR
Intervention: Spironolactone 100 mg/day
Number of subjects: 52
Study: 32735221

Group type: EXPERIMENTAL
Intervention: Feel Stress Free app (6 weeks)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Feel Stress Free app (4 weeks)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Wait-list control (6 weeks)
Number of subjects: 168
Study: 35574717

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study: 35541826

Group type: EXPERIMENTAL
Intervention: Pressure Control Ventilation (PCV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Volume Control Ventilation (VCV)
Number of subjects: 30
Study: 32176703

Group type: EXPERIMENTAL
Intervention: Ivermectin, diethylcarbamazine, and albendazole (IDA)
Number of subjects: 3612

Group type: COMPARATOR
Intervention: Diethylcarbamazine and albendazole (DA)
Number of subjects: 3612

Group type: EXPERIMENTAL
Intervention: IDA
Number of subjects: 3612

Group type: COMPARATOR
Intervention: DA
Number of subjects: 3612
Study: 35157170

Group type: EXPERIMENTAL
Intervention: Negative framing (70% likely to occur)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Positive framing (30% unlikely to occur)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control (no-headache instruction)
Number of subjects: 174
Study: 34349841

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine-cisplatin (OV-CDDP) - 60–80 mg/m2 OV days 1 and 8 with 80 mg/m2 CDDP day 1
Number of subjects: 114

Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin (GEM-CDDP) - 1250 mg/m2 GEM days 1 and 8 with 75 mg/m2 CDDP day 1
Number of subjects: 114
Study: 35546725

Group type: EXPERIMENTAL
Intervention: CAD/CAM titanium abutments bonded to titanium bases
Number of subjects: 24

Group type: COMPARATOR
Intervention: One-piece CAD/CAM titanium abutments
Number of subjects: 24
Study: 34231375

Group type: EXPERIMENTAL
Intervention: High-salt diet (250 mEq sodium/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low-salt diet (50 mEq sodium/day)
Number of subjects: 9
Study: 35384398

Group type: EXPERIMENTAL
Intervention: 200-mg generic pazopanib tablet
Number of subjects: 32

Group type: COMPARATOR
Intervention: 200-mg branded pazopanib tablet
Number of subjects: 32
Study: 35468807

Group type: EXPERIMENTAL
Intervention: Nontargeted HCV screening
Number of subjects: 125000

Group type: COMPARATOR
Intervention: Targeted HCV screening
Number of subjects: 125000
Study: 32682457

Group type: EXPERIMENTAL
Intervention: TAS‐118 (S‐1 plus leucovorin) plus oxaliplatin
Number of subjects: 711

Group type: COMPARATOR
Intervention: S‐1 plus cisplatin
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: TAS‐118 plus oxaliplatin
Number of subjects: 711
Study: 33288325

Group type: COMPARATOR
Intervention: Non-prep (NP) veneers
Number of subjects: 64

Group type: COMPARATOR
Intervention: Minimal-invasive (MI) veneers
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Semi-invasive (SI) veneers
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Invasive (I) veneers
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Veneer-composite interface
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tooth-composite interface
Number of subjects: 64
Study: 33034942

Group type: EXPERIMENTAL
Intervention: Intralesional PRP (platelet-rich plasma)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone acetonide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (intralesional normal saline)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intralesional PRP
Number of subjects: 50
Study: 35871933

Group type: EXPERIMENTAL
Intervention: Crocin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Saffron
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 34342293

Group type: EXPERIMENTAL
Intervention: Deep convolutional neural network (CNN) for recognizing AG
Number of subjects: 2741

Group type: EXPERIMENTAL
Intervention: Deep convolutional neural network (CNN) for recognizing GIM
Number of subjects: 2741
Study: 32737973

Group type: EXPERIMENTAL
Intervention: RAS‐supported multimodal balance training
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Regular multimodal balance training
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control intervention (educational program)
Number of subjects: 154
Study: 35436167

Group type: EXPERIMENTAL
Intervention: Why improve my hearing? Telecare Tool
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 57
Study: 32930848

Group type: EXPERIMENTAL
Intervention: 320 mg anthocyanins daily for 12 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 35138410

Group type: EXPERIMENTAL
Intervention: Total shoulder arthroplasty (TSA) followed by usual care
Number of subjects: 102

Group type: COMPARATOR
Intervention: 12-week exercise program (exercise only)
Number of subjects: 102
Study: 35782094

Group type: EXPERIMENTAL
Intervention: Choice group (n = 49)
Number of subjects: 148

Group type: COMPARATOR
Intervention: No-choice group (n = 49)
Number of subjects: 148
Study: 33023671

Group type: EXPERIMENTAL
Intervention: Convalescent plasma infusion (two bags of 238-337 ml each on day 1 and day 2)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard of care (no convalescent plasma)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Convalescent plasma infusion
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 174
Study: 34001840

Group type: EXPERIMENTAL
Intervention: Core stability exercises on stable support surfaces
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Core stability exercises on unstable support surfaces
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard physiotherapy (Control)
Number of subjects: 84
Study: 33607790

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (conventional treatment only)
Number of subjects: 120
Study: 32729819

Group type: EXPERIMENTAL
Intervention: Test formulation of memantine 10-mg tablet under fasting condition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Test formulation of memantine 10-mg tablet under fed condition
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation (Ebixa 10-mg tablet)
Number of subjects: 20
Study: 36181632

Group type: EXPERIMENTAL
Intervention: VOM ethanol infusion
Number of subjects: 129
Study: 34601833

Group type: EXPERIMENTAL
Intervention: Patency group (size 10 K-file carried 01mm beyond working length)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Non-patency group (file carried till working length)
Number of subjects: 240
Study: 35642688

Group type: EXPERIMENTAL
Intervention: Individual counselling based on the GATHER model
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 33704435

Group type: EXPERIMENTAL
Intervention: Vaccinated patients (received at least one dose of mRNA COVID-19 vaccine)
Number of subjects: 39156

Group type: COMPARATOR
Intervention: Unvaccinated patients (did not receive vaccine)
Number of subjects: 39156

Group type: EXPERIMENTAL
Intervention: Vaccinated patients >10 days after 1st dose
Number of subjects: 39156

Group type: EXPERIMENTAL
Intervention: Vaccinated patients >0 days after 2nd dose
Number of subjects: 39156
Study: 32043961

Group type: EXPERIMENTAL
Intervention: Wearable device (WHOOP, Inc.) providing feedback regarding sleep information for 1 week
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Wearable device (WHOOP, Inc.)
Number of subjects: 32
Study: 33780297

Group type: EXPERIMENTAL
Intervention: HAPA intervention (n = 28)
Number of subjects: 61
Study: 33982936

Group type: EXPERIMENTAL
Intervention: Risk prediction assay (TissueCypher)
Number of subjects: 155
Study: 36078648

Group type: EXPERIMENTAL
Intervention: Online Pilates intervention (PE group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-exercise group (CON)
Number of subjects: 16
Study: 33599056

Group type: EXPERIMENTAL
Intervention: Cognitive training sessions on executive function (8 sessions)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no psychological training)
Number of subjects: 61
Study: 33205064

Group type: EXPERIMENTAL
Intervention: AKR-001 (Fc-FGF21 fusion protein) at 70 mg QW
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AKR-001 (Fc-FGF21 fusion protein)
Number of subjects: 0
Study: 616389359

Group type: EXPERIMENTAL
Intervention: Meticulous dissection by specially preservation of supraclavicular nerves during open reduction and internal fixation (ORIF)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional ORIF
Number of subjects: 37
Study: 34391872

Group type: EXPERIMENTAL
Intervention: Metformin (maximum dose 2,000 mg/d)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 34376438

Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum (TQL) block with 0.375% ropivacaine 20 mL on each side
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oblique subcostal transversus abdominis plane (OSTAP) block with 0.375% ropivacaine 20 mL on each side
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transmuscular quadratus lumborum (TQL) block
Number of subjects: 0
Study: 35484009

Group type: EXPERIMENTAL
Intervention: Internal rotation taping
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: External rotation taping
Number of subjects: 15

Group type: COMPARATOR
Intervention: No taping
Number of subjects: 15
Study: 32066598

Group type: EXPERIMENTAL
Intervention: Targeted mild hypercapnia (TMH) with PaCO2 45-55 mm Hg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Targeted normocapnia (TN) with PaCO2 35-40 mm Hg
Number of subjects: 40
Study: 34853883

Group type: EXPERIMENTAL
Intervention: Maternal calcium intake during pregnancy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Maternal bone resorption (measured by urinary excretion of cross-linked N-telopeptides) during pregnancy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Offspring body mass index
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Offspring sex (boys vs girls)
Number of subjects: 103
Study: 33966763

Group type: EXPERIMENTAL
Intervention: Seven message variations
Number of subjects: 2607
Study: 35531319

Group type: EXPERIMENTAL
Intervention: Intravenous analgesia with tramadol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (Intravenous analgesia with sufentanil)
Number of subjects: 200
Study: 32466016

Group type: EXPERIMENTAL
Intervention: Alpha 1 antitrypsin (A1AT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 35869955

Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 78

Group type: COMPARATOR
Intervention: Controlled-release dinoprostone vaginal insert
Number of subjects: 78
Study: 34325645

Group type: EXPERIMENTAL
Intervention: Zinc (Zn) supplementation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 35161508

Group type: EXPERIMENTAL
Intervention: Game-based dual-task (DT) balance exercise program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional balance training
Number of subjects: 20
Study: 34562728

Group type: EXPERIMENTAL
Intervention: Cognitive training plus treatment as usual
Number of subjects: 46

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 46
Study: 34580638

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: COMPARATOR
Intervention: Exenatide vs Placebo
Number of subjects: 65

Group type: COMPARATOR
Intervention: Insulin Glargine vs Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Insulin Glargine vs Exenatide
Number of subjects: 65
Study: 33024061

Group type: EXPERIMENTAL
Intervention: Endoscopic Vacuum-Assisted Closure (EVAC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Self-Expandable Metallic Stent (SEMS)
Number of subjects: 39
Study: 35018648

Group type: EXPERIMENTAL
Intervention: Propofol target-controlled infusion (TCI) with effect compartment concentration set to 3 μg/ml
Number of subjects: 175
Study: 34189335

Group type: EXPERIMENTAL
Intervention: Active deep brain stimulation (DBS) targeting the ventral capsule/ventral striatum (VC/VS) region for three months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham deep brain stimulation
Number of subjects: 27
Study: 35422002

Group type: EXPERIMENTAL
Intervention: Closed-loop oxygen control
Number of subjects: 45

Group type: COMPARATOR
Intervention: Manual oxygen titration
Number of subjects: 45
Study: 34234368

Group type: EXPERIMENTAL
Intervention: MyDiabetesPlan (an online goal-setting patient decision aid)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: MyDiabetesPlan
Number of subjects: 17
Study: 35254967

Group type: EXPERIMENTAL
Intervention: MAD + AMT
Number of subjects: 21

Group type: COMPARATOR
Intervention: MAD
Number of subjects: 21

Group type: COMPARATOR
Intervention: AMT alone
Number of subjects: 21
Study: 34081773

Group type: EXPERIMENTAL
Intervention: eHealth tool PREPAREforYourCare.org (PREPARE)
Number of subjects: 0
Study: 32848379

Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol (5/5 μg and 2.5/5 μg)
Number of subjects: 3100

Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol (5/5 μg)
Number of subjects: 3100

Group type: COMPARATOR
Intervention: Tiotropium (5 μg and 2.5 μg) and Olodaterol (5 μg)
Number of subjects: 3100
Study: 36356989

Group type: EXPERIMENTAL
Intervention: Bictegravir (BIC) 50 mg/emtricitabine (FTC) 200 mg/tenofovir alafenamide (TAF) 25 mg (Biktarvy) taken two times per day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dolutegravir-based regimen (standard of care)
Number of subjects: 120
Study: 33011649

Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Single-Disorder Protocols (SDPs)
Number of subjects: 179
Study: 35854230

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - personalized diet and exercise recommendations, pedometer device for monitoring physical activity.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control Group (CG) - baseline general advice and materials for patients undergoing RT.
Number of subjects: 300
Study: 34544618

Group type: EXPERIMENTAL
Intervention: FIO2 = 0.95 (group TH)
Number of subjects: 23

Group type: COMPARATOR
Intervention: FIO2 = 0.65 (group TL)
Number of subjects: 23
Study: 33345866

Group type: EXPERIMENTAL
Intervention: 20-mL liposomal bupivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: 20-mL 0.25% plain bupivacaine
Number of subjects: 120
Study: 35243855

Group type: EXPERIMENTAL
Intervention: Step-up protocol (recombinant FSH 75IU sc/day, increasing to 150IU if no response after 7 days)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Step-down protocol (recombinant FSH 150IU sc/day, decreasing to 75IU after 5 days)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Step-up protocol
Number of subjects: 145

Group type: COMPARATOR
Intervention: Step-down protocol
Number of subjects: 145
Study: 32300774

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to smoking initiation
Number of subjects: 996576
Study: 35798016

Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg orally once daily plus atezolizumab 1200 mg intravenously every 3 weeks
Number of subjects: 837

Group type: COMPARATOR
Intervention: Sorafenib 400 mg orally twice daily
Number of subjects: 837

Group type: EXPERIMENTAL
Intervention: Single-agent cabozantinib 60 mg orally once daily
Number of subjects: 837
Study: 34598050

Group type: EXPERIMENTAL
Intervention: Parent-only social learning Cognitive Behavioral Therapy (SLCBT)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Education condition (control)
Number of subjects: 316
Study: 32205810

Group type: EXPERIMENTAL
Intervention: Extended lymph node dissection (LND) during radical cystectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimally invasive radical cystectomy with LND
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overall major complication, readmission and mortality rates
Number of subjects: 0
Study: 33217147

Group type: EXPERIMENTAL
Intervention: Remote ischaemic per‐conditioning (RIC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (sham)
Number of subjects: 26
Study: 34162490

Group type: EXPERIMENTAL
Intervention: Direct-to-mothership model
Number of subjects: 0
Study: 34002707

Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac sodium
Number of subjects: 90

Group type: COMPARATOR
Intervention: 500 mg mefenamic acid
Number of subjects: 90
Study: 32946537

Group type: EXPERIMENTAL
Intervention: Health insurance
Number of subjects: 10143

Group type: EXPERIMENTAL
Intervention: Extra fees for hospital admission
Number of subjects: 10143
Study: 35467436

Group type: EXPERIMENTAL
Intervention: Virtually delivered web-based legacy intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human-animal interaction intervention for children with cancer
Number of subjects: 0
Study: 32815892

Group type: EXPERIMENTAL
Intervention: Gaze and postural stability (GPS) group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Strength and aerobic exercise (SAE) group
Number of subjects: 28
Study: 36173726

Group type: EXPERIMENTAL
Intervention: Minimally invasive envelope flap
Number of subjects: 60
Study: 34495375

Group type: COMPARATOR
Intervention: isCGM
Number of subjects: 170

Group type: COMPARATOR
Intervention: ABC
Number of subjects: 170

Group type: COMPARATOR
Intervention: ABC+isCGM
Number of subjects: 170

Group type: COMPARATOR
Intervention: isCGM alone
Number of subjects: 170
Study: 32842971

Group type: EXPERIMENTAL
Intervention: TAU + FNC (Treatment as Usual + Informal Social Network Intervention)
Number of subjects: 105

Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 105
Study: 35639621

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 33455531

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SP)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Unrepaired rupture (patients' ratings)
Number of subjects: 254
Study: 34807321

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study: 33941941

Group type: EXPERIMENTAL
Intervention: Pain Rating index group (PRi group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Systolic blood pressure group (SBP group)
Number of subjects: 44
Study: 33799350

Group type: EXPERIMENTAL
Intervention: 9 month regimen consisting of levofloxacin, rifampicin, ethambutol, pyrazinamide, plus a second‐line injectable in the first 3 months
Number of subjects: 132